Massachusetts Financial Services CO Dynavax Technologies Corp Transaction History

Massachusetts Financial Services CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	SELL	$13.09 - $14.98 $42,005 - $48,070	-3,209 Reduced 3.06%	101,557 $1.42 Million
Q3 2023 Nov 08, 2023	SELL	$12.64 - $14.99 $50,762 - $60,199	-4,016 Reduced 3.69%	104,766 $1.55 Million
Q2 2023 Aug 09, 2023	SELL	$9.85 - $13.17 $25,235 - $33,741	-2,562 Reduced 2.3%	108,782 $1.41 Million
Q1 2023 May 10, 2023	BUY	$9.44 - $11.88 $860,295 - $1.08 Million	91,133 Added 450.91%	111,344 $1.09 Million
Q4 2022 Feb 13, 2023	SELL	$10.27 - $13.29 $1.33 Million - $1.72 Million	-129,367 Reduced 86.49%	20,211 $215,000
Q3 2022 Nov 09, 2022	BUY	$9.93 - $17.44 $1.49 Million - $2.61 Million	149,578 New	149,578 $1.56 Million

275

130M

451K

203K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.61B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

Stay updated on Massachusetts Financial Services CO with notifications on news.